Ignacio Munoz-Sanjuan, Ph.D. - Publications

Johns Hopkins University, Baltimore, MD 

36 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2016 Benraiss A, Wang S, Herrlinger S, Li X, Chandler-Militello D, Mauceri J, Burm HB, Toner M, Osipovitch M, Jim Xu Q, Ding F, Wang F, Kang N, Kang J, Curtin PC, ... ... Munoz-Sanjuan I, et al. Human glia can both induce and rescue aspects of disease phenotype in Huntington disease. Nature Communications. 7: 11758. PMID 27273432 DOI: 10.1038/ncomms11758  1
2016 Beaumont V, Mrzljak L, Dijkman U, Freije R, Heins M, Rassoulpour A, Tombaugh G, Gelman S, Bradaia A, Steidl E, Gleyzes M, Heikkinen T, Lehtimäki K, Puoliväli J, Kontkanen O, ... ... Munoz-Sanjuan I, et al. The novel KMO inhibitor CHDI-340246 leads to a restoration of electrophysiological alterations in mouse models of Huntington's disease. Experimental Neurology. PMID 27163548 DOI: 10.1016/J.Expneurol.2016.05.005  1
2015 Glorioso JC, Cohen JB, Carlisle DL, Munoz-Sanjuan I, Friedlander RM. Moving toward a gene therapy for Huntington's disease. Gene Therapy. 22: 931-933. PMID 26633828 DOI: 10.1038/Gt.2015.102  1
2015 Wityak J, McGee KF, Conlon MP, Song RH, Duffy BC, Clayton B, Lynch M, Wang G, Freeman E, Haber J, Kitchen DB, Manning DD, Ismail J, Khmelnitsky Y, Michels P, et al. Lead optimization toward proof-of-concept tools for Huntington's disease within a 4-(1H-pyrazol-4-yl)pyrimidine class of pan-JNK inhibitors. Journal of Medicinal Chemistry. 58: 2967-87. PMID 25760409 DOI: 10.1021/jm5013598  1
2015 Orsatti L, Speziale R, Orsale MV, Caretti F, Veneziano M, Zini M, Monteagudo E, Lyons K, Beconi M, Chan K, Herbst T, Toledo-Sherman L, Munoz-Sanjuan I, Bonelli F, Dominguez C. A single-run liquid chromatography mass spectrometry method to quantify neuroactive kynurenine pathway metabolites in rat plasma. Journal of Pharmaceutical and Biomedical Analysis. 107: 426-31. PMID 25668794 DOI: 10.1016/j.jpba.2015.01.030  1
2015 Toledo-Sherman LM, Prime ME, Mrzljak L, Beconi MG, Beresford A, Brookfield FA, Brown CJ, Cardaun I, Courtney SM, Dijkman U, Hamelin-Flegg E, Johnson PD, Kempf V, Lyons K, Matthews K, ... ... Munoz-Sanjuan I, et al. Development of a series of aryl pyrimidine kynurenine monooxygenase inhibitors as potential therapeutic agents for the treatment of Huntington's disease. Journal of Medicinal Chemistry. 58: 1159-83. PMID 25590515 DOI: 10.1021/jm501350y  1
2014 Lu XH, Mattis VB, Wang N, Al-Ramahi I, van den Berg N, Fratantoni SA, Waldvogel H, Greiner E, Osmand A, Elzein K, Xiao J, Dijkstra S, de Pril R, Vinters HV, Faull R, ... ... Munoz-Sanjuan I, et al. Targeting ATM ameliorates mutant Huntingtin toxicity in cell and animal models of Huntington's disease. Science Translational Medicine. 6: 268ra178. PMID 25540325 DOI: 10.1126/Scitranslmed.3010523  1
2014 Howland DS, Munoz-Sanjuan I. Mind the gap: models in multiple species needed for therapeutic development in Huntington's disease. Movement Disorders : Official Journal of the Movement Disorder Society. 29: 1397-403. PMID 25155258 DOI: 10.1002/mds.26008  1
2014 Sutcliffe JS, Beaumont V, Watson JM, Chew CS, Beconi M, Hutcheson DM, Dominguez C, Munoz-Sanjuan I. Efficacy of selective PDE4D negative allosteric modulators in the object retrieval task in female cynomolgus monkeys (Macaca fascicularis). Plos One. 9: e102449. PMID 25050979 DOI: 10.1371/journal.pone.0102449  1
2014 Menalled LB, Kudwa AE, Oakeshott S, Farrar A, Paterson N, Filippov I, Miller S, Kwan M, Olsen M, Beltran J, Torello J, Fitzpatrick J, Mushlin R, Cox K, McConnell K, ... ... Munoz-Sanjuan I, et al. Genetic deletion of transglutaminase 2 does not rescue the phenotypic deficits observed in R6/2 and zQ175 mouse models of Huntington's disease. Plos One. 9: e99520. PMID 24955833 DOI: 10.1371/Journal.Pone.0099520  1
2014 Beaumont V, Park L, Rassoulpour A, Dijkman U, Heikkinen T, Lehtimaki K, Kontkanen O, Al Nackkash R, Bates GP, Gleyzes M, Steidl E, Ramboz S, Murphy C, Beconi MG, Dominguez C, ... Munoz-Sanjuan I, et al. The PDE1/5 Inhibitor SCH-51866 Does Not Modify Disease Progression in the R6/2 Mouse Model of Huntington's Disease. Plos Currents. 6. PMID 24558637 DOI: 10.1371/currents.hd.3304e87e460b4bb0dc519a29f4deccca  1
2014 Todd D, Gowers I, Dowler SJ, Wall MD, McAllister G, Fischer DF, Dijkstra S, Fratantoni SA, van de Bospoort R, Veenman-Koepke J, Flynn G, Arjomand J, Dominguez C, Munoz-Sanjuan I, Wityak J, et al. A monoclonal antibody TrkB receptor agonist as a potential therapeutic for Huntington's disease. Plos One. 9: e87923. PMID 24503862 DOI: 10.1371/Journal.Pone.0087923  1
2014 Bard J, Wall MD, Lazari O, Arjomand J, Munoz-Sanjuan I. Advances in huntington disease drug discovery: novel approaches to model disease phenotypes. Journal of Biomolecular Screening. 19: 191-204. PMID 24196395 DOI: 10.1177/1087057113510320  1
2013 Bürli RW, Luckhurst CA, Aziz O, Matthews KL, Yates D, Lyons KA, Beconi M, McAllister G, Breccia P, Stott AJ, Penrose SD, Wall M, Lamers M, Leonard P, Müller I, ... ... Munoz-Sanjuan I, et al. Design, synthesis, and biological evaluation of potent and selective class IIa histone deacetylase (HDAC) inhibitors as a potential therapy for Huntington's disease. Journal of Medicinal Chemistry. 56: 9934-54. PMID 24261862 DOI: 10.1021/jm4011884  1
2012 Prime ME, Brookfield FA, Courtney SM, Gaines S, Marston RW, Ichihara O, Li M, Vaidya D, Williams H, Pedret-Dunn A, Reed L, Schaertl S, Toledo-Sherman L, Beconi M, Macdonald D, et al. Irreversible 4-Aminopiperidine Transglutaminase 2 Inhibitors for Huntington's Disease. Acs Medicinal Chemistry Letters. 3: 731-5. PMID 24900540 DOI: 10.1021/ml3001352  1
2012 Wityak J, Prime ME, Brookfield FA, Courtney SM, Erfan S, Johnsen S, Johnson PD, Li M, Marston RW, Reed L, Vaidya D, Schaertl S, Pedret-Dunn A, Beconi M, Macdonald D, et al. SAR Development of Lysine-Based Irreversible Inhibitors of Transglutaminase 2 for Huntington's Disease. Acs Medicinal Chemistry Letters. 3: 1024-8. PMID 24900424 DOI: 10.1021/ml300241m  1
2012 Heikkinen T, Lehtimäki K, Vartiainen N, Puoliväli J, Hendricks SJ, Glaser JR, Bradaia A, Wadel K, Touller C, Kontkanen O, Yrjänheikki JM, Buisson B, Howland D, Beaumont V, Munoz-Sanjuan I, et al. Characterization of neurophysiological and behavioral changes, MRI brain volumetry and 1H MRS in zQ175 knock-in mouse model of Huntington's disease. Plos One. 7: e50717. PMID 23284644 DOI: 10.1371/journal.pone.0050717  1
2012 Beconi M, Aziz O, Matthews K, Moumné L, O'Connell C, Yates D, Clifton S, Pett H, Vann J, Crowley L, Haughan AF, Smith DL, Woodman B, Bates GP, Brookfield F, ... ... Munoz-Sanjuan I, et al. Oral administration of the pimelic diphenylamide HDAC inhibitor HDACi 4b is unsuitable for chronic inhibition of HDAC activity in the CNS in vivo. Plos One. 7: e44498. PMID 22973455 DOI: 10.1371/journal.pone.0044498  1
2012 Beconi MG, Yates D, Lyons K, Matthews K, Clifton S, Mead T, Prime M, Winkler D, O'Connell C, Walter D, Toledo-Sherman L, Munoz-Sanjuan I, Dominguez C. Metabolism and pharmacokinetics of JM6 in mice: JM6 is not a prodrug for Ro-61-8048. Drug Metabolism and Disposition: the Biological Fate of Chemicals. 40: 2297-306. PMID 22942319 DOI: 10.1124/dmd.112.046532  1
2012 Prime ME, Andersen OA, Barker JJ, Brooks MA, Cheng RK, Toogood-Johnson I, Courtney SM, Brookfield FA, Yarnold CJ, Marston RW, Johnson PD, Johnsen SF, Palfrey JJ, Vaidya D, Erfan S, et al. Discovery and structure-activity relationship of potent and selective covalent inhibitors of transglutaminase 2 for Huntington's disease. Journal of Medicinal Chemistry. 55: 1021-46. PMID 22224594 DOI: 10.1021/jm201310y  1
2011 Beconi MG, Howland D, Park L, Lyons K, Giuliano J, Dominguez C, Munoz-Sanjuan I, Pacifici R. Pharmacokinetics of memantine in rats and mice. Plos Currents. 3: RRN1291. PMID 22307216 DOI: 10.1371/currents.RRN1291  1
2011 Maillard MC, Brookfield FA, Courtney SM, Eustache FM, Gemkow MJ, Handel RK, Johnson LC, Johnson PD, Kerry MA, Krieger F, Meniconi M, Muñoz-Sanjuán I, Palfrey JJ, Park H, Schaertl S, et al. Exploiting differences in caspase-2 and -3 Sâ‚‚ subsites for selectivity: structure-based design, solid-phase synthesis and in vitro activity of novel substrate-based caspase-2 inhibitors. Bioorganic & Medicinal Chemistry. 19: 5833-51. PMID 21903398 DOI: 10.1016/j.bmc.2011.08.020  1
2011 Munoz-Sanjuan I, Bates GP. The importance of integrating basic and clinical research toward the development of new therapies for Huntington disease. The Journal of Clinical Investigation. 121: 476-83. PMID 21285520 DOI: 10.1172/JCI45364  1
2010 Schaertl S, Prime M, Wityak J, Dominguez C, Munoz-Sanjuan I, Pacifici RE, Courtney S, Scheel A, Macdonald D. A profiling platform for the characterization of transglutaminase 2 (TG2) inhibitors. Journal of Biomolecular Screening. 15: 478-87. PMID 20395409 DOI: 10.1177/1087057110366035  1
2008 Bilsland JG, Wheeldon A, Mead A, Znamenskiy P, Almond S, Waters KA, Thakur M, Beaumont V, Bonnert TP, Heavens R, Whiting P, McAllister G, Munoz-Sanjuan I. Behavioral and neurochemical alterations in mice deficient in anaplastic lymphoma kinase suggest therapeutic potential for psychiatric indications. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. 33: 685-700. PMID 17487225 DOI: 10.1038/Sj.Npp.1301446  1
2007 Beaumont V, Thompson SA, Choudhry F, Nuthall H, Glantschnig H, Lipfert L, David GR, Swain CJ, McAllister G, Munoz-Sanjuan I. Evidence for an enhancement of excitatory transmission in adult CNS by Wnt signaling pathway modulation. Molecular and Cellular Neurosciences. 35: 513-24. PMID 17588772 DOI: 10.1016/j.mcn.2007.03.004  1
2005 Muñoz-Sanjuán I, Brivanlou AH. Induction of ectopic olfactory structures and bone morphogenetic protein inhibition by Rossy, a group XII secreted phospholipase A2. Molecular and Cellular Biology. 25: 3608-19. PMID 15831466 DOI: 10.1128/MCB.25.9.3608-3619.2005  1
2003 Levine AJ, Munoz-Sanjuan I, Bell E, North AJ, Brivanlou AH. Fluorescent labeling of endothelial cells allows in vivo, continuous characterization of the vascular development of Xenopus laevis. Developmental Biology. 254: 50-67. PMID 12606281 DOI: 10.1016/S0012-1606(02)00029-5  1
2003 Bell E, Muñoz-Sanjuán I, Altmann CR, Vonica A, Brivanlou AH. Cell fate specification and competence by Coco, a maternal BMP, TGFbeta and Wnt inhibitor. Development (Cambridge, England). 130: 1381-9. PMID 12588853 DOI: 10.1242/dev.00344  1
2002 Muñoz-Sanjuán I, Bell E, Altmann CR, Vonica A, Brivanlou AH. Gene profiling during neural induction in Xenopus laevis: regulation of BMP signaling by post-transcriptional mechanisms and TAB3, a novel TAK1-binding protein. Development (Cambridge, England). 129: 5529-40. PMID 12403722 DOI: 10.1242/dev.00097  1
2002 Muñoz-Sanjuán I, Brivanlou AH. Neural induction, the default model and embryonic stem cells. Nature Reviews. Neuroscience. 3: 271-80. PMID 11967557 DOI: 10.1038/nrn786  1
2001 Muñoz-Sanjuán I, Cooper MK, Beachy PA, Fallon JF, Nathans J. Expression and regulation of chicken fibroblast growth factor homologous factor (FHF)-4 during craniofacial morphogenesis. Developmental Dynamics : An Official Publication of the American Association of Anatomists. 220: 238-45. PMID 11241832 DOI: 10.1002/1097-0177(20010301)220:3<238::Aid-Dvdy1104>3.0.Co;2-T  1
2000 Muñoz-Sanjuán I, Fallon JF, Nathans J. Expression and regulation of chicken fibroblast growth factor homologous factor (FHF)-4 at the base of the developing limbs. Mechanisms of Development. 95: 101-12. PMID 10906454 DOI: 10.1016/S0925-4773(00)00336-1  1
2000 Munoz-Sanjuan I, Smallwood PM, Nathans J. Isoform diversity among fibroblast growth factor homologous factors is generated by alternative promoter usage and differential splicing. The Journal of Biological Chemistry. 275: 2589-97. PMID 10644718 DOI: 10.1074/Jbc.275.4.2589  1
1999 Munoz-Sanjuan I, Simandl BK, Fallon JF, Nathans J. Expression of chicken fibroblast growth factor homologous factor (FHF)-1 and of differentially spliced isoforms of FHF-2 during development and involvement of FHF-2 in chicken limb development. Development (Cambridge, England). 126: 409-21. PMID 9847253  1
1996 Smallwood PM, Munoz-Sanjuan I, Tong P, Macke JP, Hendry SH, Gilbert DJ, Copeland NG, Jenkins NA, Nathans J. Fibroblast growth factor (FGF) homologous factors: new members of the FGF family implicated in nervous system development. Proceedings of the National Academy of Sciences of the United States of America. 93: 9850-7. PMID 8790420 DOI: 10.1073/Pnas.93.18.9850  1
Show low-probability matches.